SOLV vs VVVV: Which Is the Better Buy in 2026?

Last updated November 2026

Short answer

SOLV is the larger of the two ($14.53B market cap): the incumbent the market prices for continued execution (11.33x forward earnings, beta 0.75). VVVV is the smaller challenger ($786.28M): more room to run, but more to prove. If the story you believe is SOLV's (Recurring consumable and software revenue), SOLV is the more direct way to own it; if it is VVVV's (More U.S. practices, and more use per practice), VVVV is.

Before you buy: how SOLV and VVVV affect your concentration

The metrics above tell you which is the marginally better business. The bigger risk for most people is not picking the slightly worse stock, it is over-concentrating. SOLV and VVVV share themes, so owning both, or adding either to what you already hold, can quietly push a large share of your portfolio into one bet.

This is the part a generic comparison page cannot answer, because it depends on what you own. Connect your brokerage and Walnut shows your real, combined SOLV and VVVV exposure, flags overlap with your existing positions, and tells you if adding one would tip you past a concentration you are comfortable with, read-only by default, with your login staying at your broker. Walnut is not an investment adviser.

What does Solventum (SOLV) do?

Solventum is a healthcare company that was spun off from 3M in 2024, combining 3M's former Health Care business into a standalone public company. It operates across three main healthcare segments: medical surgical products (wound care, advanced dressings, surgical supplies, infection prevention), dental and orthodontic solutions, and health information systems (clinical documentation, coding, and revenue-cycle software for hospitals). It sold its purification and filtration business (water and biopharma filtration) in September 2025. The company makes money selling consumable medical products to hospitals and clinics and software and services to health systems. As a recent spin-off, Solventum's story centers on standing up independent operations, paying down debt inherited at separation, stabilizing growth, and improving margins. It holds established brands and large installed bases in several niches. Headquartered in Maplewood, Minnesota, it serves customers across hospital and dental end markets globally. Over the twelve months to September 2026, revenue was about $8.16 billion and the company employed roughly 20,600 people.

Full SOLV guide

What does vVARDIS Holding AG (VVVV) do?

vVARDIS Holding AG is a dental products company based in Zug, Switzerland, run by its co-founders and co-CEOs Haley and Goly Abivardi, two dentists who previously ran a chain of Swiss clinics. Its business is one product family, Curodont, a peptide-containing liquid a dentist applies to an early-stage cavity in a few minutes, without drilling or anaesthetic. The peptides form a scaffold inside the lesion that lets minerals from saliva rebuild the enamel. In the United States the product is sold as Curodont Repair Fluoride Plus, which the FDA regulates as an over-the-counter drug because of its sodium fluoride content. That route got it to market quickly, and it also means the FDA has made no finding on its safety or effectiveness.

Full VVVV guide

SOLV vs VVVV: how do they differ?

Both fit overlapping themes, but they are not interchangeable. Here is what each one depends on.

  • SOLV drivers: Recurring consumable and software revenue; Spin-off self-help and margin expansion.
  • VVVV drivers: More U.S. practices, and more use per practice; AI cavity detection as a referral channel.

Which fits which kind of investor

A faster-growing, richer-valued name usually swings harder, so it suits a longer horizon and a higher tolerance for volatility; a steadier, more cash-generative business suits a more conservative or income-minded investor. A useful test is which set of risks you could hold through a drawdown: As a recent spin-off, Solventum carries meaningful debt taken on at separation (about $5.3 billion against roughly $0.45 billion of cash in late 2026) and must prove it can grow organically after years inside 3M, where the business reportedly underinvested; organic revenue fell about 2.8% in the September 2026 quarter (about 3.5% growth excluding the ERP order reversal), and Dental sales fell about 7%. For VVVV, almost all revenue comes from one product family, and in the U.S.

SOLV or VVVV: which should you pick?

With growth, valuation and volatility this close (or not yet reported for one side), the drivers above are what separate SOLV from VVVV. Many investors hold both, but since they share themes, that is a concentrated bet, not diversification. Decide deliberately and check overlap. For the full detail, see the SOLV and VVVV guides.

SOLV vs VVVV: the full fundamentals

SOLV. Solventum still trades at a discount to faster-growing medtech peers (about 11x forward earnings and under 2x sales in November 2026), a gap explained by slow top-line growth, elevated post-spin debt, and the work still required to prove independent execution. The trailing P/E near 96x is distorted the other way now that the large September 2025 quarter has rolled out of the twelve-month window and GAAP results carry separation costs. Analysts expect about $7.26 of EPS in 2026 and ~$7.54 in 2027, and the average target among 13 analysts rose to about $98.38 after Q3, with BTIG, Piper Sandler and Jefferies all lifting targets.

VVVV. The market value depends on how shares are counted. After the IPO there are about 38.6 million Class A shares plus 143.9 million Class B voting shares held by the founders, but each Class B share carries one-tenth the economic rights of a Class A share, so it counts as about 14.4 million Class A equivalents. Some early press reports quoted a valuation above $4 billion by counting Class B shares as full shares. On ~53.0 million economic shares at ~$14.81 the company is worth ~$0.78 billion, about 14 times trailing revenue of ~$56 million and about 26 times 2025 revenue. No analyst coverage exists yet; the underwriters' quiet period typically ends 25 days after the IPO, which points to early December 2026.

Headline figures (approximate, November 2026): SOLV shows revenue (ttm) ~$8.16 billion, revenue growth ~-7% reported, ~-2.8% organic in Q3 2026, margins (ttm) gross ~54%, GAAP operating ~6%; Q3 adjusted operating ~19.9%, q3 2026 adjusted eps $1.45 vs ~$1.34 consensus; VVVV shows revenue (ttm through september 2026, preliminary) ~$56M (Q4 2025 plus 9M 2026 midpoint), revenue (9m 2026, preliminary) ~$47.7M to $49.2M, up ~114% to 121%, gross margin (9m 2026, preliminary) ~86%, net loss (9m 2026, preliminary) ~$39.7M to $41.3M (adjusted EBITDA ~-$9.3M).

The bottom line: SOLV vs VVVV

SOLV and VVVV are related but distinct: same themes, different businesses and risks. Neither wins in the abstract, and whichever you pick is worth sizing so one theme does not take over your portfolio. Walnut can show your combined SOLV and VVVV exposure against your real portfolio. It is not an investment adviser.

Wondering how SOLV or VVVV fits the portfolio you already own? Walnut is an AI investing app that connects your brokerage read-only and answers questions like that about your actual holdings: overlap, concentration, and how each position tracks the S&P 500. Compare the best AI portfolio analyzers or see the best AI investing apps in 2026.

Your questions about Solventum

Ask Walnut's AI anything about SOLV and see how it fits what you own.

FAQ

What is the difference between SOLV and VVVV?

+

Solventum is a healthcare company that was spun off from 3M in 2024, combining 3M's former Health Care business into a standalone public company. vVARDIS Holding AG is a dental products company based in Zug, Switzerland, run by its co-founders and co-CEOs Haley and Goly Abivardi, two dentists who previously ran a chain of Swiss clinics. They show up together because they share investment themes, but they are different businesses, so the better fit depends on which thesis you are expressing.

Is SOLV or VVVV the better stock?

+

Neither is universally better. SOLV is the larger incumbent; VVVV is the smaller challenger. Walnut is informational, not investment advice. Compare what each does, the tie-breaker metrics above, and the risks, then decide which fits your thesis and what you already own.

Which is cheaper, SOLV or VVVV?

+

A lower multiple is not automatically the better buy: a richer valuation can be justified by faster growth, and a lower one can reflect real risk. Weigh the multiple against how fast each business is compounding.

Should you own both SOLV and VVVV?

+

Because they share themes, owning both concentrates you in that theme. That can be intentional (a focused bet) or accidental (less diversification than it looks). Walnut can show your combined exposure across both, and whether adding either over-concentrates you, before you buy.

What are the risks of SOLV vs VVVV?

+

SOLV: As a recent spin-off, Solventum carries meaningful debt taken on at separation (about $5.3 billion against roughly $0.45 billion of cash in late 2026) and must prove it can grow organically after years inside 3M, where the business reportedly underinvested; organic revenue fell about 2.8% in the September 2026 quarter (about 3.5% growth excluding the ERP order reversal), and Dental sales fell about 7%. Several segments face slow growth and competitive pressure from larger, better-capitalized rivals. Standing up independent systems has already disrupted ordering once, and the planned Health Information Systems separation adds a new round of execution risk and a stated margin headwind. Pricing pressure from hospital cost-cutting, exposure to elective-procedure volumes, and any legacy liabilities associated with former 3M products are additional concerns. Reported GAAP profit is uneven (net income swung from about $1.27 billion in the September 2025 quarter to a loss of about $12 million in the September 2026 quarter), so the trailing P/E near 96x says little about underlying earnings power, and some analysts remain skeptical, with Rothschild & Co Redburn keeping a sell rating and a $75 target in October 2026. Free cash flow guidance of only $200 to $300 million for 2026 limits how fast debt can come down, and portfolio reshaping could be dilutive if executed at unattractive valuations. VVVV: Almost all revenue comes from one product family, and in the U.S. nearly all of it flows through one distributor: Henry Schein accounted for about 90% of sales in the first half of 2026, up from 62% a year earlier, under an exclusive agreement that runs to December 31, 2029. Heartland Dental, a large dental service organization, is another key customer. Curodont Repair Fluoride Plus is sold under the FDA's over-the-counter route because of its fluoride, and the company itself warns regulators could disagree with that classification and require a different pathway. Dentists already have entrenched, reimbursed options in fluoride varnish, sealants and fillings, and the clinical case for Curodont rests largely on European studies. The company is still losing money, with an accumulated deficit of ~$256.3 million, and carries expensive floating-rate debt. Governance is concentrated: the Abivardi sisters hold all the Class B voting shares and about 87% of voting power, and they have pledged about 10.3 million shares as collateral for CHF 105 million (~$128 million) of personal loans, with talks to pledge up to 2.87 million more. A forced sale of pledged shares would land on the public float. The stock has traded for only a week, priced below its range, has since fallen about 18% under the offer price, and faces a 180-day lock-up expiry in May 2027. It has no analyst coverage yet, and it will report its first full quarter as a public company in 2027.

Walnut is informational, not investment advice. This page is descriptive and not a recommendation to buy or sell SOLV or VVVV; figures are approximate and dated (as of November 2026). Verify current data before investing.